Evidence map›Paper›PMID 35467000›Full record

ArticleAmerican journal of clinical pathology2022

Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.

Michael P Zaleski, Hui Chen, Sinchita Roy-Chowdhuri, Keyur P Patel, Rajyalakshmi Luthra, Mark J Routbort, Ashish M Kamat, Jianjun Gao, Arlene Siefker-Radtke, Bogdan Czerniak and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michael P ZaleskiDepartment Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui ChenDepartment Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sinchita Roy-ChowdhuriDepartment Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9447-7701
Keyur P PatelDepartment Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rajyalakshmi LuthraDepartment Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark J RoutbortDepartment Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashish M KamatDepartment Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun GaoGenitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Arlene Siefker-RadtkeGenitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bogdan CzerniakDepartment Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Charles C GuoDepartment Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

objectivesTo investigate the gene mutational profile of urachal carcinoma in correlation with its clinicopathologic features.

methodsWe analyzed genetic mutations in 30 cases of urachal carcinoma by next-generation sequencing (NGS) test. Histologic slides and clinical data were reviewed.

resultsThe patients included 21 men and 9 women, with a mean age of 53 years (range, 24-75 years). The urachal carcinomas included mucinous (11), enteric (10), signet ring cell (8), and high-grade neuroendocrine (1) subtypes. Targeted NGS analysis demonstrated genetic mutations in all the urachal tumors (mean, 2; range, 1-4). TP53 was the most mutated gene (25), followed by KRAS (9) and GNAS (8) genes. TP53 mutations were more common in the signet ring cell subtype (7/8), and GNAS mutations were present only in the mucinous (5/11) and signet ring cell subtypes (3/8) but not in the enteric subtype (0/10). KRAS mutations were significantly associated with cancer stage IV (P = .02) and younger patient age (P = .046). Furthermore, the presence of KRAS mutations in urachal carcinoma portended a poorer overall survival (P = .006).

conclusionsUrachal carcinoma demonstrates frequent gene mutations that are associated with distinct clinicopathologic features. Gene mutation may underlie the development and progression of this aggressive disease.

Indexed as

Carcinoma, Signet Ring CellUrinary Bladder NeoplasmsAdultAgedDNA Mutational AnalysisFemaleHumansMaleMiddle AgedMutationProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)Gene mutationsGNASKRASNext-generation sequencingTP53Urachal carcinoma

Identifiers

PMID35467000
PMCPMC9350833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.